Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + axitinib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Avelumab + axitinib is a combination therapy consisting of two distinct drugs used together for the first-line treatment of advanced renal cell carcinoma (RCC). Avelumab is a fully human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. Axitinib is an oral small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3, thereby blocking angiogenesis and tumor growth. The combination was approved based on clinical trial data showing significant improvements in progression-free survival and objective response rates compared to standard therapies in patients with advanced RCC[1][2][3][5].
- Brand names
- Bavencio + Inlyta
- Other names
- avelumab plus axitinibavelumab and axitinibBAVENCIO plus INLYTA
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)
Beyond the preview
Go deeper on avelumab + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + axitinib.